The single-arm, open-label study enrolls 40 adults aged 1880 who have inadequate response to prior biologics, with participants receiving intravenous induction therapy every 4 weeks for 12 weeks followed by subcutaneous maintenance injections every 4 weeks for up to 2 years
Koska J, Sands M, Burciu C, D'Souza KM, Raravikar K, Liu J, Truran S, Franco DA, Schwartz EA, Schwenke DC
One such investigation, known as the SUSTAIN-6 trial, was a moderate-sized trial that examined use of the once-weekly injectable agent semaglutide on cardiovascular outcomes when compared with placebo
Many patients notice changes within the first few weeks, though results build over months
Constipation: This is a major consideration for IBS-C patients on GLP-1, but even those with IBS-M or IBS-D should be aware of it